Pre-Operative Acetazolamide Administration for Post-Operative Abdominal Pain Releif

Effect of Pre-Operative Administration of Acetazolamide on Post-Operational Shoulder Referred Pain and Abdominal Pain in Laparoscopic Cholecystectomy Candidates: a Randomized Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017081935778N1

Enrollment

111

Registered

2017-10-29

Start date

2017-09-29

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholecystitis. Cholecystitis

Interventions

Intervention 1: Intervention group 1:In this group patients will receive 10mg/Kg of Acetazolamide. Since estimated mean weight of patients is 75 Kg, each patient will be administered 6 halved 250-mg t

Prevention

Placebo

Intervention group 1:In this group patients will receive 10mg/Kg of Acetazolamide. Since estimated mean weight of patients is 75 Kg, each patient will be administered 6 halved 250-mg tablets (total of

Control group:A placebo with identical appearance will be provided for each patient in this group. All patients in this group will be administered 6 halved placebo tablets 1 hour before laparoscopy op

Intervention group 2:In this group patients will receive 5mg/Kg of Acetazolamide. Since estimated mean weight of patients is 75 Kg, each patient will be administered 3 halved 250-mg tablets (total of

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Subjects must be candidates for laparoscopic cholecystectomy (ages 18 to 65) Exclusion criteria: Subject with a history of any hematologic disorders; chronic metabolic acidosis; chronic obstructive pulmonary disease; kidney transplantation; allergy to sufonamides; patients with present history of electrolyte disturbances; CNS dysfunction; renal failure or creatinine level higher than 2mg/dl; pregnancy; any liver diseases; or patients with ongoing diuretic treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Abdominal Pain. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: VAS questionnaire.;Modified Aldrete Score. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Physical examination for scoring; and pulse oxymetry.	—

Measure

Time frame

Abdominal Pain. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: VAS questionnaire.;Modified Aldrete Score. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Physical examination for scoring; and pulse oxymetry.

—

Secondary

Measure	Time frame
Time before requesting opioid. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Timer.;Amount of opioid used to deteriorate pain. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Report by resident.;Distribution of pain location. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Physical Examination.;Time before discharge from hospital. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Timer.	—

Measure

Time frame

Time before requesting opioid. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Timer.;Amount of opioid used to deteriorate pain. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Report by resident.;Distribution of pain location. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Physical Examination.;Time before discharge from hospital. Timepoint: first, second, and third 30 minutes within the operation, and first,second, and third 30 minutes within recovery, also at the time of discharge. Method of measurement: Timer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPayman Soleimani

Isfahan University of Medical Sciences

kiarrach23@yahoo.com+98 31 3625 7840

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026